title: [Extended field radiotherapy and high-dose brachytherapy combined with chemotherapy in patients with locally advanced cervical carcinoma].
abstract: OBJECTIVE
  Evaluation of results of extended field radiotherapy and high-dose rate brachytherapy combined with chemotherapy in patients with locally advanced cervical carcinoma.
  
  
  METHODS
  A retrospective study.
  
  
  METHODS
  Department of Oncology and Radiotherapy, University Hospital Hradec Králové.
  
  
  METHODS
  Forty five patients with stage IIB - IVA cervical cancer and radiologically suspicious pelvic and/or paraaortic lymph nodes were treated at the Dept. of Oncology and Radiotherapy Hradec Králové with pelvic and paraaortic radiotherapy, high-dose rate brachytherapy and concomitant chemotherapy with cisplatin or cisplatin and paclitaxel.
  
  
  RESULTS
  The 3-years disease free survival estimate was 64%. Hematological toxicity was the most limiting factor of concomitant chemotherapy. Late toxicity grade III and IV was observed in 7 patients. One patient underwent surgery due to ileus caused by lymphoma.
  
  
  CONCLUSIONS
  Concomitant chemoradiotherapy with paraaortic fields results in high tumor control but also significant acute and late toxicity. New techniques of radiotherapy, such as intensity modulated radiotherapy, may improve the therapeutic ratio.
authors.affiliation: Klinika onkologie a radioterapie, FN a LF Hradec Králové. petera@fnhk.cz
authors.forename: J
authors.initials: J
authors.lastname: Petera
authors.forename: K
authors.initials: K
authors.lastname: Odrázka
authors.forename: M
authors.initials: M
authors.lastname: Dolezel
authors.forename: Z
authors.initials: Z
authors.lastname: Zoul
authors.forename: M
authors.initials: M
authors.lastname: Vaculíková
authors.forename: J
authors.initials: J
authors.lastname: Sefrová
authors.forename: I
authors.initials: I
authors.lastname: Sirák
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001918:Brachytherapy; D002277:Carcinoma / Q000188:drug therapy / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D011879:Radiotherapy Dosage; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*